Arbutus Biopharma (ABUS) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Arbutus Biopharma (NASDAQ:ABUS) from a buy rating to a hold rating in a report published on Friday, Zacks.com reports.

According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. “

A number of other equities analysts have also recently weighed in on ABUS. ValuEngine cut Arbutus Biopharma from a hold rating to a sell rating in a report on Wednesday, May 1st. BidaskClub raised Arbutus Biopharma from a hold rating to a buy rating in a report on Tuesday, March 5th. Chardan Capital reaffirmed a buy rating and issued a $6.50 price target on shares of Arbutus Biopharma in a report on Sunday, March 10th. Finally, Echelon Wealth Partners reaffirmed a hold rating on shares of Arbutus Biopharma in a report on Monday, March 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $6.25.

NASDAQ ABUS opened at $2.20 on Friday. The stock has a market capitalization of $129.05 million, a P/E ratio of -2.16 and a beta of 1.61. Arbutus Biopharma has a twelve month low of $2.18 and a twelve month high of $12.60. The company has a quick ratio of 11.50, a current ratio of 12.75 and a debt-to-equity ratio of 0.06.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.16). The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.18 million. Arbutus Biopharma had a negative return on equity of 95.26% and a negative net margin of 1,237.92%. As a group, equities research analysts expect that Arbutus Biopharma will post -1.32 EPS for the current year.

A number of large investors have recently bought and sold shares of ABUS. BNP Paribas Arbitrage SA purchased a new stake in Arbutus Biopharma during the 1st quarter worth approximately $26,000. The Manufacturers Life Insurance Company increased its stake in Arbutus Biopharma by 140.4% during the 1st quarter. The Manufacturers Life Insurance Company now owns 26,188 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 15,296 shares in the last quarter. Legal & General Group Plc increased its stake in Arbutus Biopharma by 15.8% during the 4th quarter. Legal & General Group Plc now owns 28,407 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 3,867 shares in the last quarter. State of Wisconsin Investment Board increased its stake in Arbutus Biopharma by 29.9% during the 1st quarter. State of Wisconsin Investment Board now owns 47,300 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 10,900 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Arbutus Biopharma by 45.9% during the 4th quarter. Rhumbline Advisers now owns 49,032 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 15,416 shares in the last quarter. Institutional investors own 42.59% of the company’s stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

See Also: What is Forex?

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.